Therefore, CD19 targeted CAR T cells have been extensively evaluated for treatment of hematological cancers such as acute lymphoblastic leukemia (ALL), diffuse large B cell lymphoma, chronic lymphocytic leukemia, and B cell non-Hodgkin lymphomas [99,148]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.